Show simple item record

dc.contributor.authorMoliner, L
dc.contributor.authorSpurgeon, Laura
dc.contributor.authorCalifano, Raffaele
dc.date.accessioned2023-03-20T15:44:01Z
dc.date.available2023-03-20T15:44:01Z
dc.date.issued2023en
dc.identifier.citationMoliner L, Spurgeon L, Califano R. Controversies in NSCLC: which second-line strategy after chemo-immunotherapy? ESMO open. 2023 Feb 13;8(2):100879. PubMed PMID: 36791668. Pubmed Central PMCID: PMC9958277 Myers Squibb, Roche, Merck Sharp & Dohme, Boehringer Ingelheim, Takeda, Bayer, Sanofi, Pharmamar, Lilly Oncology, Janssen, Amgen, and Novartis. All other authors have declared no conflicts of interest. Epub 2023/02/16. eng.en
dc.identifier.pmid36791668en
dc.identifier.doi10.1016/j.esmoop.2023.100879en
dc.identifier.urihttp://hdl.handle.net/10541/626067
dc.description.abstractNoneen
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.esmoop.2023.100879en
dc.titleControversies in NSCLC: which second-line strategy after chemo-immunotherapy?en
dc.typeOtheren
dc.contributor.departmentDepartment of Medical Oncology, The Christie Hospital NHS Foundation Trust, Manchesteren
dc.identifier.journalESMO Openen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record